NCT07327489Recruiting
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies
Source: ClinicalTrials.gov · Last updated 29 Jun 2026
Brief summary (registry, in English)
This study will collect tumor specimens with correlated clinical and demographic data from patients who are undergoing a biopsy or similar procedure to obtain tumor tissue as a normal course of their medical management or diagnostic work-up for suspected or confirmed cancer.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 2000 (estimated)
- First submitted
- 19 Dec 2025
- Start date
- 14 Apr 2025
- Primary completion date
- 30 Apr 2035
- Lead sponsor
- Elephas
- Diseases
- Triple-negative breast cancer, Head and neck cancer, Kidney cancer, Bladder cancer, Melanoma, Endometrial cancer, Lung cancer, Colorectal cancer, Liver and biliary tract cancer
- NCT number
- NCT07327489
What you commit to
- Study type: Observational
- Planned participants: 2000
- From 14 Apr 2025 to the primary completion date, 30 Apr 2035
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Have a known auto-immune disease or prior condition (prior organ transplant, chronic kidney or liver disease) that renders them ineligible for immunotherapy (IO) treatment.
Other illness
- Severely immunocompromised person(s). Examples include patients on immunosuppressants, HIV positive patients on antiretrovirals, post transplantation patients.
Other
- Pregnant person(s).
Who the study is looking for
- Able and willing to provide informed consent for participation
- Age ≥18 years at time of consent.
- Have a suspected or confirmed cancer diagnosis that is to be evaluated by means of a biopsy.
- Subjects who are newly diagnosed or have suspected cancer must be treatment-naïve at the time of biopsy. All other subjects should have the biopsy performed before starting their next line of treatment.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| JPS Health Network Coordinator of this site? Confirm its status | Forth Worth | United States | Recruiting |
| Mercy Hospital - FTS Coordinator of this site? Confirm its status | Fort Smith | United States | Recruiting |
| Frederick Health Hospital Coordinator of this site? Confirm its status | Frederick | United States | Recruiting |
| Mercy Hospital - OKC Coordinator of this site? Confirm its status | Oklahoma City | United States | Recruiting |
| Mercy Hospital - SPG Coordinator of this site? Confirm its status | Springfield | United States | Recruiting |
| Mercy Hospital -STL Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| Mercy Hospital South Coordinator of this site? Confirm its status | St Louis | United States | Recruiting |
| Baylor Scott and White Biorepository Coordinator of this site? Confirm its status | Temple | United States | Not yet recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.